Report on an unusual case of leprosy from Germany: just an exception of the rule?

[1]  G. Bretzel,et al.  Development of a combined RLEP/16S rRNA (RT) qPCR assay for the detection of viable M. leprae from nasal swab samples , 2019, BMC Infectious Diseases.

[2]  Juan Camilo Alzate,et al.  Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15 , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  S. Cole,et al.  Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae , 2018, Nature Communications.

[4]  L. Goulart,et al.  Molecular Evidence for the Aerial Route of Infection of Mycobacterium leprae and the Role of Asymptomatic Carriers in the Persistence of Leprosy. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  I. Belinchón,et al.  Epidemiology of Leprosy in Spain: The Role of the International Migration , 2016, PLoS neglected tropical diseases.

[6]  M. Duthie,et al.  Comparative evaluation of antibody detection tests to facilitate the diagnosis of multibacillary leprosy , 2016, Applied Microbiology and Biotechnology.

[7]  A. Aubry,et al.  Update on the epidemiology, diagnosis, and treatment of leprosy. , 2015, Medecine et maladies infectieuses.

[8]  C. Massone,et al.  Imported leprosy in Italy , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  Robert Koch-Institut.  Steckbriefe seltener und importierter Infektionskrankheiten , 2011 .

[10]  V. Shetty,et al.  Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai. , 2011, Leprosy review.

[11]  D. Lockwood,et al.  Leprosy now: epidemiology, progress, challenges, and research gaps. , 2011, The Lancet. Infectious diseases.

[12]  Diana J L Williams,et al.  Molecular Determination of Mycobacterium leprae Viability by Use of Real-Time PCR , 2009, Journal of Clinical Microbiology.

[13]  R. Gelber,et al.  The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. , 2004, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[14]  G. Ebenezer,et al.  Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy? , 2004, Indian journal of leprosy.

[15]  D. Lockwood,et al.  Treatment of leprosy , 2004, BMJ : British Medical Journal.

[16]  D. Lockwood,et al.  Leprosy , 2004, The Lancet.

[17]  A. Alvarenga,et al.  Use of a different buffer system in the phenolic glycolipid-I ELISA. , 1992, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[18]  P. Klatser,et al.  Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? , 1992, Leprosy review.

[19]  C. Shivannavar,et al.  In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index and FDA-EB fluorescent staining in Mycobacterium leprae. , 1988, Leprosy review.

[20]  C. Shepard,et al.  Relationship Between the Staining Quality of Mycobacterium leprae and Infectivity for Mice , 1971, Infection and immunity.

[21]  D. H. McRae,et al.  Mycobacterium leprae in Mice: Minimal Infectious Dose, Relationship Between Staining Quality and Infectivity, and Effect of Cortisone , 1965, Journal of bacteriology.

[22]  R. A. M. C. H. I. N-A-L.  Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? , 2014 .